Four-Drug Combo Ups Pancreatic Cancer Survival
Posted on: Thursday, 12 May 2005, 09:00 CDT
HealthDay News -- A combination therapy involving four chemotherapy drugs could double survival rates for patients with tough-to-treat pancreatic cancer, researchers report.
The Italian study included pancreatic cancer patients aged 18 to 70 years. Fifty-two received a combo treatment of cisplatin, epirubicin, gemcitabine and fluorouracil -- called the PEGF regimen -- while another 47 received gemcitabine alone.
Because it is often caught too late, pancreatic cancer remains one of the most lethal malignancies. Gemcitabine is currently regarded as the standard treatment for the disease, with clinical trials finding it provides patients with a 17 to 28 percent one-year survival rate.
Four months into treatment, 60 percent of the patients in the PEGF group were alive without progressive disease, compared with just 28 percent of patients taking gemcitabine alone, the researchers report. One-year survival was 40 percent for the PEGF patients and 20 percent for those taking gemcitabine alone, they add.
More of the PEGF patients experienced blood-related side effects, but these were manageable and didn't harm their quality of life, the study authors said.
Writing in this week's online edition of the journal The Lancet Oncology, the researchers stressed that a larger study is needed before PEGF could be regarded as a new standard therapy.
"We have shown that patients allocated PEGF had a more favorable outcome in terms of progression-free survival and overall survival than did those allocated standard treatment with gemcitabine," researcher Dr. Michele Reni said in a prepared statement. The investigator remains hopeful, however, that "PEGF might be a feasible and effective first-line treatment for patients with advanced pancreatic cancer."
More information
The National Cancer Institute has more about pancreatic cancer.
SOURCE: The Lancet Oncology, news release, May 9, 2005~-GEN~~DRUG~
Source: HealthSCOUT
Related Articles
- Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
- Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
- Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors
- Study Suggests Survival Benefit From Radioactive Microsphere Therapy in Patients With Colorectal Cancer Liver Metastases Who Have Failed Chemotherapy
- AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer By 2016
- Hollis-Eden's Cancer Treatment Promising in Preclinical Study
- Renowned Interventional Pulmonologist Joins Cancer Treatment Centers of America
- Researchers Announce New Predictor for Lung Cancer Treatment and Survival
- Palliative Treatment of Painful Disseminated Bone Metastases With ^Sup 186^Rhenium-HEDP in Patients With Lung Cancer
- Studies Challenge Breast Cancer Treatment
 |
 |
User Comments (0)
RSS Feeds